{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:40:52Z","timestamp":1778035252751,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11060-025-04998-y","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:38:12Z","timestamp":1742384292000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Breast cancer spine metastases treated with stereotactic body radiation therapy: patient outcomes and predictors"],"prefix":"10.1007","volume":"173","author":[{"given":"Bryce","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshetu","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Detsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremie","family":"Larouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pejman","family":"Maralani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sten","family":"Myrehaug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chai-Lin","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang Liang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"4998_CR1","doi-asserted-by":"publisher","unstructured":"Ju DG, Yurter A, Gokaslan ZL, Sciubba DM (Aug. 2014) Diagnosis and surgical management of breast cancer metastatic to the spine. World J Clin Oncol 5(3):263. https:\/\/doi.org\/10.5306\/WJCO.V5.I3.263","DOI":"10.5306\/WJCO.V5.I3.263"},{"key":"4998_CR2","doi-asserted-by":"publisher","unstructured":"Briasoulis E, Karavasilis V, Kostadima L, Ignatiadis M, Fountzilas G, Pavlidis N (2004) Metastatic breast carcinoma confined to bone portrait of a clinical entity. https:\/\/doi.org\/10.1002\/cncr.20545","DOI":"10.1002\/cncr.20545"},{"key":"4998_CR3","doi-asserted-by":"publisher","unstructured":"Thibault I et al (Dec. 2015) Response assessment after stereotactic body radiotherapy for spinal metastasis: A report from the spine response assessment in Neuro-Oncology (SPINO) group. Lancet Oncol 16(16):e595\u2013e603. https:\/\/doi.org\/10.1016\/S1470-2045(15)00166-7","DOI":"10.1016\/S1470-2045(15)00166-7"},{"key":"4998_CR4","doi-asserted-by":"publisher","unstructured":"Sahgal A et al (2020) CCTG SC.24\/TROG 17.06: A Randomized Phase II\/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases. Int J Radiat Oncol Biol Phys 108(5)1397\u20131398. https:\/\/doi.org\/10.1016\/J.IJROBP.2020.09.019","DOI":"10.1016\/J.IJROBP.2020.09.019"},{"key":"4998_CR5","doi-asserted-by":"publisher","unstructured":"Zeng KL et al (2022) Mature Local Control and Reirradiation Rates Comparing Spine Stereotactic Body Radiation Therapy With Conventional Palliative External Beam Radiation Therapy, Int J Radiat Oncol Biol Phys 114(2)293\u2013300. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.043","DOI":"10.1016\/j.ijrobp.2022.05.043"},{"key":"4998_CR6","doi-asserted-by":"publisher","unstructured":"Abugharib A et al (2022) Spine Stereotactic Body Radiotherapy for Prostate Cancer Metastases and the Impact of Hormone Sensitivity Status on Local Control. Neurosurgery 90(6)743\u2013749. https:\/\/doi.org\/10.1227\/NEU.0000000000001909","DOI":"10.1227\/NEU.0000000000001909"},{"key":"4998_CR7","doi-asserted-by":"publisher","unstructured":"Sprave T et al (Aug. 2018) Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol 128(2):274\u2013282. https:\/\/doi.org\/10.1016\/J.RADONC.2018.04.030","DOI":"10.1016\/J.RADONC.2018.04.030"},{"key":"4998_CR8","doi-asserted-by":"publisher","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A (Sep. 2021) Breast Cancer-Epidemiology, risk factors, classification, prognostic markers, and current treatment Strategies-An updated review. Cancers (Basel) 13(17). https:\/\/doi.org\/10.3390\/CANCERS13174287","DOI":"10.3390\/CANCERS13174287"},{"key":"4998_CR9","doi-asserted-by":"publisher","unstructured":"Schaub SK et al (2019) Strategies to Mitigate Toxicities from Stereotactic Body Radiation Therapy for Spine Metastases, Clin Neurosurg 85(6)729\u2013740. https:\/\/doi.org\/10.1093\/NEUROS\/NYZ213","DOI":"10.1093\/NEUROS\/NYZ213"},{"key":"4998_CR10","doi-asserted-by":"publisher","unstructured":"Zeng KL et al (Dec. 2021) Prognostic factors associated with surviving less than 3 months vs greater than 3 years specific to spine stereotactic body radiotherapy and late adverse events. Neurosurgery 89:S. https:\/\/doi.org\/10.1093\/NEUROS\/NYAA583_S120","DOI":"10.1093\/NEUROS\/NYAA583_S120"},{"key":"4998_CR11","doi-asserted-by":"publisher","unstructured":"Tsai CJ et al (2024) Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. The Lancet 403(10422):171\u2013182. https:\/\/doi.org\/10.1016\/S0140-6736(23)01857-3","DOI":"10.1016\/S0140-6736(23)01857-3"},{"key":"4998_CR12","doi-asserted-by":"publisher","unstructured":"Chmura SJ et al (2022) NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). Journal of Clinical Oncology 40(16 suppl). https:\/\/doi.org\/10.1200\/JCO.2022.40.16_SUPPL.1007","DOI":"10.1200\/JCO.2022.40.16_SUPPL.1007"},{"key":"4998_CR13","doi-asserted-by":"publisher","unstructured":"Hyde D et al (Mar. 2012) Spine stereotactic body radiotherapy utilizing Cone-Beam CT Image-Guidance with a robotic couch: intrafraction motion analysis accounting for all six degrees of freedom. Int J Radiat Oncol Biol Phys 82(3):e555\u2013e562. https:\/\/doi.org\/10.1016\/J.IJROBP.2011.06.1980","DOI":"10.1016\/J.IJROBP.2011.06.1980"},{"key":"4998_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1470-2045(15)00166-7","volume":"16","author":"I Thibault","year":"2015","unstructured":"Thibault I et al (2015) Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the spine response assessment in Neuro-Oncology (SPINO) group. Rev Lancet Oncol 16:595\u2013603 [Online]. Available: www.thelancet.com\/oncology","journal-title":"Rev Lancet Oncol"},{"key":"4998_CR15","doi-asserted-by":"publisher","unstructured":"Moore-Palhares D et al (2023) 30 Gy in 4 Stereotactic Body Radiotherapy Fractions for Complex Spinal Metastases: Mature Outcomes Supporting This Novel Regimen. Neurosurgery 93(4)813\u2013823 https:\/\/doi.org\/10.1227\/neu.0000000000002498","DOI":"10.1227\/neu.0000000000002498"},{"key":"4998_CR16","doi-asserted-by":"publisher","unstructured":"Taori S et al (Apr. 2024) The role of spine stereotactic radiosurgery for patients with breast cancer metastases. J Neurooncol 167(2):257\u2013266. https:\/\/doi.org\/10.1007\/s11060-024-04599-1","DOI":"10.1007\/s11060-024-04599-1"},{"key":"4998_CR17","doi-asserted-by":"publisher","unstructured":"Yan B, Ramadan S, Jerzak KJ, Louie AV, Donovan E (Jul. 2023) The effectiveness and safety of stereotactic body radiation therapy (SBRT) in the treatment of oligoprogressive breast cancer: A systematic review. Curr Oncol 30(7):6976. https:\/\/doi.org\/10.3390\/CURRONCOL30070505","DOI":"10.3390\/CURRONCOL30070505"},{"key":"4998_CR18","doi-asserted-by":"publisher","unstructured":"Weykamp F et al (Jun. 2020) Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast Cancer. Front Oncol 10:523609. https:\/\/doi.org\/10.3389\/FONC.2020.00987\/BIBTEX","DOI":"10.3389\/FONC.2020.00987\/BIBTEX"},{"key":"4998_CR19","doi-asserted-by":"publisher","unstructured":"Zeng KL et al (2023) Dose-Escalated 2-Fraction Spine Stereotactic Body Radiation Therapy: 28 Gy Versus 24 Gy in 2 Daily Fractions, Int J Radiat Oncol Biol Phys 115(3)686\u2013695. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.076","DOI":"10.1016\/j.ijrobp.2022.09.076"},{"key":"4998_CR20","doi-asserted-by":"publisher","unstructured":"Zeng KL et al (Mar. 2021) Local control and patterns of failure for \u2018Radioresistant\u2019 spinal metastases following stereotactic body radiotherapy compared to a \u2018Radiosensitive\u2019 reference J Neurooncol 152(1):173\u201382. https:\/\/doi.org\/10.1007\/S11060-020-03691-6\/METRICS","DOI":"10.1007\/S11060-020-03691-6\/METRICS"},{"key":"4998_CR21","doi-asserted-by":"publisher","unstructured":"Kowalchuk RO et al (Jun. 2024) Assessment of minimum target dose as a predictor of local failure after spine SBRT. Radiother Oncol 195. https:\/\/doi.org\/10.1016\/j.radonc.2024.110260","DOI":"10.1016\/j.radonc.2024.110260"},{"issue":"1","key":"4998_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijrobp.2010.08.021","volume":"82","author":"A Sahgal","year":"2012","unstructured":"Sahgal A et al (2012) Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 82(1):107\u2013116. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.08.021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4998_CR23","doi-asserted-by":"publisher","unstructured":"Li X et al (Jan. 2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279\u2013287. https:\/\/doi.org\/10.1007\/S10549-016-4059-6\/FIGURES\/2","DOI":"10.1007\/S10549-016-4059-6\/FIGURES\/2"},{"key":"4998_CR24","doi-asserted-by":"publisher","unstructured":"Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ (Jun. 2012) Locoregional recurrence after breast cancer surgery: A systematic review by receptor phenotype. Breast Cancer Res Treat 133(3):831\u2013841. https:\/\/doi.org\/10.1007\/S10549-011-1891-6\/METRICS","DOI":"10.1007\/S10549-011-1891-6\/METRICS"},{"key":"4998_CR25","doi-asserted-by":"publisher","unstructured":"Ito K, Saito T, Nakamura N, Imano N, Hoskin P (Dec. 2022) Stereotactic body radiotherapy versus conventional radiotherapy for painful bone metastases: a systematic review and meta-analysis of randomised controlled trials. Radiat Oncol 17(1):1\u201310. https:\/\/doi.org\/10.1186\/S13014-022-02128-W\/TABLES\/3","DOI":"10.1186\/S13014-022-02128-W\/TABLES\/3"},{"key":"4998_CR26","doi-asserted-by":"publisher","unstructured":"Burgess L et al (Oct. 2024) Predictors of vertebral compression fracture following spine stereotactic body radiotherapy vary with cause: iatrogenic or in conjunction with local failure. Int J Radiat Oncol Biol Phys 120(2):e220. https:\/\/doi.org\/10.1016\/J.IJROBP.2024.07.496","DOI":"10.1016\/J.IJROBP.2024.07.496"},{"key":"4998_CR27","doi-asserted-by":"publisher","unstructured":"Tsai CJ et al (Dec. 2022) Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression Trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers. Int J Radiat Oncol Biol Phys 114(5):1061. https:\/\/doi.org\/10.1016\/J.IJROBP.2022.09.008","DOI":"10.1016\/J.IJROBP.2022.09.008"},{"key":"4998_CR28","doi-asserted-by":"publisher","unstructured":"David SP et al (Nov. 2023) Stereotactic ablative body radiotherapy (SABR) for oligoprogressive ER-Positive breast Cancer (AVATAR): A phase II prospective multicenter trial. Int J Radiat Oncol Biol Phys 117(4):e6. https:\/\/doi.org\/10.1016\/J.IJROBP.2023.08.033","DOI":"10.1016\/J.IJROBP.2023.08.033"},{"key":"4998_CR29","doi-asserted-by":"publisher","unstructured":"Alomran R et al (Dec. 2021) Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). BMC Cancer 21(1):1\u20139. https:\/\/doi.org\/10.1186\/S12885-021-08042-W\/TABLES\/2","DOI":"10.1186\/S12885-021-08042-W\/TABLES\/2"},{"key":"4998_CR30","doi-asserted-by":"publisher","unstructured":"Sahgal A et al (Jul. 2021) Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial. Lancet Oncol 22(7):1023\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(21)00196-0","DOI":"10.1016\/S1470-2045(21)00196-0"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04998-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-04998-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04998-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T08:44:49Z","timestamp":1748249089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-04998-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["4998"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-04998-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arjun Sahgal declares that he has the following conflicts of interest: grants or contracts from Elekta AB, Varian, Seagen Inc., and BrainLAB with payments to his institution, consulting fees from Varian, Elekta (Gamma Knife Icon), and BrainLAB with payments to himself, payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events for AstraZeneca, Elekta AB, Varian, BrainLAB, Seagen Inc., Cerapedics, and Carbo Fix with payments to himself, support for attending meetings and\/or travel by Elekta, Varian, and BrainLAB with payments to himself, is in a leadership role as the President of the International Stereotactic Radiosurgery Society, the Co-Chair of the AO Spine Knowledge Forum Tumor, and member of the Elekta MR Linac Research Consortium and is a Clinical Steering Committee member, and chairs the Elekta Oligometastases Group and the Elekta Gamma Knife Icon Group.Hanbo Chen declares that he has the following conflicts of interest: a research grant from Elekta and speaker\u2019s honoraria payment from Novartis for lectures, presentations, or educational events. Chia-Lin Tseng declares that he has the following conflicts of interest: payment or honoraria for past educational seminars with Elekta, and travel and accommodation expenses to support attending meetings by Elekta. He is also a member of the Elekta MR-Linac Research Consortium.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}